GlassScriptPhysician profile
Chris Terry Derk
NPI 1609899210
$66,093.87
in general payments reported to CMS, 2019-2025
10 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,449 · 2020: $6,472 · 2021: $3,257 · 2022: $13K · 2023: $2,060 · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,193.33 |
| Food and Beverage | $119.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $35,400.00 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim International Gmbh | $9,729.00 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,776.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $5,183.70 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,600.00 | 2022 | |
| Csl Behring | $1,852.30 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $885.00 | 2023-2025 | |
| Zoll Medical Corporation | $508.33 | 2025 | Defibrillator |
| E.R. Squibb & Sons, L.L.C. | $119.04 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $40.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Derk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.